Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA254
  • Published: 
Download guidance (PDF)

Changes after publication

January 2014: implementation section updated to clarify that fingolimod is recommended as an option for treating highly active relapsing–remitting multiple sclerosis. Additional minor maintenance update also carried out.